| Literature DB >> 35566001 |
Ágota Pető1,2,3, Dóra Kósa1,2,3, Ádám Haimhoffer1,2, Dániel Nemes1, Pálma Fehér1, Zoltán Ujhelyi1, Miklós Vecsernyés1, Judit Váradi1, Ferenc Fenyvesi1, Adina Frum4, Felicia Gabriela Gligor4, Laura Grațiela Vicaș5, Eleonora Marian5, Tunde Jurca5, Annamaria Pallag5, Mariana Eugenia Muresan6, Zoltán Tóth7, Ildikó Bácskay1,3.
Abstract
Philadelphus coronarius is a versatile plant and its use in folk medicine has a long tradition; however, scientifically, the medical utilization of the herb is a less explored research field. The aim of our study was to identify and determine the quantity of the bioactive compounds of both the leaf and the flower and prepare a lyophilized product of them, from which medical ointments were formulated, since the topical application of P. coronarius has also not been studied. In vitro drug release, texture analysis and biocompatibility experiments were carried out, as well as the investigation of microbiological, antioxidant and anti-inflammatory properties. According to our results the composition and the selected excipients of the ointments have a great impact on the drug release, texture and bioavailability of the preparation. During the microbiological testing, the P. coronarius leaf was effective against Escherichia coli and Staphylococcus aureus, but it did not significantly decrease IL-4 production when it was tested on HaCaT cells. P. coronarius is a promising herb, and its topical application in antimicrobial therapy can be a useful addition to modern medical therapy.Entities:
Keywords: Philadelphus coronarius; anti-inflammatory; antimicrobial; antioxidant; chemical compounds; cytotoxicity; ointments; penetration enhancers; topical application
Mesh:
Substances:
Year: 2022 PMID: 35566001 PMCID: PMC9100982 DOI: 10.3390/molecules27092652
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Figure 1Experimental design.
Bioactive-compound content of P. coronarius leaves.
| Bioactive Compound Content (Mg Compound/100 mg) ± SD | |
|---|---|
| 7-methoxycoumarin | 0.2061 ± 0.032 |
| Chlorogenic acid | 0.0128 ± 0.0097 |
| Caffeic acid | 0.0740 ± 0.0033 |
| Delphinidin 3-rutinoside chloride | 0.3354 ± 0.047 |
| Hyperoside | 0.0514 ± 0.0071 |
| Luteolin 7-glucoside | 0.2528 ± 0.056 |
| Rutin | 0.0941 ± 0.0045 |
| T-resveratrol | 0.0602 ± 0.0026 |
In this table the bioactive-compound content of P. coronarius leaf is presented. Data represent the quantity of the isolated components from 100 mg leaf extract. From the components, delphinidin 3-rutinoside chloride, luteolin 7-glucoside and 7-methoxycoumarin are present in a high amount.
Bioactive-compound content of P. coronarius flowers.
| Bioactive-Compound Content (Mg Compound/100 mg) ± SD | |
|---|---|
| 7-methoxycoumarin | 1.6725 ± 0.372 |
| Chlorogenic acid | 0.2485 ± 0.098 |
| Ferulic acid | 0.1094 ± 0.020 |
| Gallic acid | 0.1375 ± 0.034 |
| Rosmarinic acid | 0.7674 ± 0.112 |
| Trans p-coumaric acid | 0.4387 ± 0.079 |
| Bergapten | 2.8370 ± 0.432 |
| Caffeic acid | 1.8407 ± 0.087 |
| Delphinidin 3-rutinoside chloride | 1.7928 ± 0.201 |
| Diosmin | 1.1125 ± 0.386 |
| Hyperoside | 0.2428 ± 0.042 |
| Isopimpinellin | 0.4678 ± 0.016 |
| Luteolin 7-glucoside | 0.0585 ± 0.0093 |
| Myricetin | 0.0645 ±0.0021 |
| Quercetin | 0.1449 ± 0.034 |
| Rutin | 0.4077 ± 0.015 |
| T-resveratrol | 0.5262 ± 0.027 |
In this table the bioactive-compound content of P. coronarius flower is presented. It lists the exact quantity of the components isolated from 100 mg flower extract. Bergapten, caffeic acid, delphinidin 3-rutinoside chloride and 7-methoxycoumarin are present in large quantities.
Antioxidant activity of P. coronarius leaf and flower evaluated by different methods.
| DPPH (%) | 86.63 ± 6.49 | 92.24 ± 10.09 |
| ABTS (mmol TE/g DW) | 18.37 ± 4.73 | 40.54 ± 9.77 * |
| FRAP (μmol TE/g) | 77.97 ± 46.01 | 164.62 ± 52.75 |
| Cuprac (μmol TE/mL) | 222.42 ± 21.04 | 423.35 ± 71.07 ** |
In this table antioxidant activity (means ± SD) of P. coronarius is presented with different methods. Abbreviations: GAE—Gallic-Acid Equivalent, QE—Quercetin Equivalent, DW—Dry Weight, TE—Trolox Equivalent. * indicates significant difference at p ≤ 0.0241; ** indicates significant difference at p ≤ 0.0093. Statistical analysis was carried out between the leaf and the flower by performing a t-test.
Total polyphenol and flavonoid content ± SD of P. coronarius leaf and flower.
| Polyphenols (mg GAE/100 g) | 59.31 ± 4.36 | 54.83 ± 9.74 |
| Flavonoids (mg QE/100 g) | 1.97 ± 1.49 | 1.91 ± 0.82 |
In this table total polyphenol and flavonoid content of P. coronarius leaf and flower extract is shown (means ± SD). Abbreviations: GAE—Gallic-Acid Equivalent, QE—Quercetin Equivalent.
Inhibition of different microbes by P. coronarius leaf or flower.
| Inhibition of Microbial Strains by | ||||
|---|---|---|---|---|
|
|
|
|
| |
|
| no inhibition | no inhibition | 46.4% ±3.4% | no inhibition |
|
| no inhibition | 68.6% ±5.6% | 41.5% ±2.7% | no inhibition |
In this table cell-viability values of different microbes are presented. P. coronarius flower reduced the cell viability of E. coli, while the leaf decreased the viability of S. aureus and E. coli.
Figure 2In vitro time-kill test of P. coronarius flower and leaf. The flower was not able to inhibit or delay the growth of bacteria or fungi, but the leaf was able to delay the growth of C. albicans and S. aureus compared to the control.
Figure 3Results of IL-4 ELISA. Data represent the mean of six wells ± SD. Pretreating HaCaT cells with P. coronarius leaf (5%) and flower (3% and 5%) did not significantly reduce IL-4 production. Data are expressed as means ± SD; n = 5. To compare the groups, ordinary one-way ANOVA test was carried out.
Composition of the six ointment formulations.
| Abbreviation | Leaf or Flower | Emulsifier | |
|---|---|---|---|
| Composition 1. | CMP 1 | leaf | SP70 |
| Composition 2. | CMP 2 | leaf | Tefose 63 |
| Composition 3. | CMP 3 | leaf | Sedefos 75 |
| Composition 4. | CMP 4 | flower | SP70 |
| Composition 5. | CMP 5 | flower | Tefose 63 |
| Composition 6. | CMP 6 | flower | Sedefos 75 |
Figure 4Release profiles of the different o/w ointment compositions. The best result was achieved by CMP 4, closely followed by CMP 2 and 5, while CMP 3 and 6 showed a greater sustained-diffusion profile in the experiment. Results represent the mean values of six samples ± SD.
Correlation-coefficient values of the compositions.
| Kinetic Model | ||
|---|---|---|
| Composition | Zero | First |
| CMP 1 | 0.03 | 0.37 |
| CMP 2 | 0.14 | 0.44 |
| CMP 3 | 0.59 | 0.70 |
| CMP 4 | 0.58 | 0.71 |
| CMP 5 | 0.65 | 0.75 |
| CMP 6 | 0.392 | 0.384 |
Release-rate and diffusion-coefficient values of the ointments.
| Composition | Release Rate ( | Diffusion Coefficient |
|---|---|---|
| CMP 1 | 7.47 | 3.30 |
| CMP 2 | 8.05 | 3.97 |
| CMP 3 | 5.31 | 2.36 |
| CMP 4 | 7.45 | 4.32 |
| CMP 5 | 6.57 | 3.97 |
| CMP 6 | 5.29 | 1.40 |
Difference factors to compare the different release profiles of the ointments.
| Composition |
|
|---|---|
| CMP 1 vs. CMP 2 | 6.87 |
| CMP 1 vs. CMP 3 | 31.40 |
| CMP 1 vs. CMP 4 | 2.98 |
| CMP 1 vs. CMP 5 | 14.44 |
| CMP 1 vs. CMP 6 | 24.02 |
| CMP 2 vs. CMP 3 | 36.11 |
| CMP 2 vs. CMP 4 | 9.65 |
| CMP 2 vs. CMP 5 | 20.32 |
| CMP 2 vs. CMP 6 | 29.24 |
| CMP 3 vs. CMP 4 | 29.29 |
| CMP 3 vs. CMP 5 | 24.71 |
| CMP 3 vs. CMP 6 | 9.71 |
| CMP 4 vs. CMP 5 | 11.81 |
| CMP 4 vs. CMP 6 | 21.68 |
| CMP 5 vs. CMP 6 | 11.19 |
Figure 5Results of texture-analysis studies. Resistance of the different ointments with the different surfactants. CMP 2 and 5 showed the hardest consistency, CMP 3 and 6 showed the softest consistency. Data are expressed as means ± SD; n = 5. To compare the preparations, ordinary one-way ANOVA test was carried out. Significant differences are marked in the figure with asterisks. * indicates significant difference at p < 0.05.
Figure 6In vitro cytotoxicity of the prepared ointment compositions (a); in vitro cytotoxicity of P. coronarius leaf and flower in different concentrations (b). Cell viability was calculated as the percentage of PBS. All samples turned out to be safe; cell viability was above 80% in every case. Data present the mean of six wells ± SD. One-way ANOVA test and t-test were carried out for statistical analysis. Significant differences are marked with asterisks. **** indicates statistically significant difference at p ˂ 0.0001.
Composition (CMP) of the ointments.
| CMP 1 | CMP 2 | CMP 3 | CMP 4 | CMP 5 | CMP6 | |
|---|---|---|---|---|---|---|
| Transcutol | + | + | + | + | + | + |
| SP70 | + | − | − | + | − | − |
| − | + | − | − | + | − | |
| − | − | + | − | − | + | |
| + | + | + | − | − | − | |
| − | − | − | + | + | + | |
| Cetostearyl alcohol | + | + | + | + | + | + |
| + | + | + | + | + | + | |
| + | + | + | + | + | + | |
| + | + | + | + | + | + | |
| Propylene glycol | + | + | + | + | + | + |
| + | + | + | + | + | + |
Mathematical model of drug-release profiles.
| Model | Equations [ | Graphic | |
|---|---|---|---|
| Zero-order | (5) | The graphic of the drug-dissolved fraction versus time is linear. | |
| First-order | (6) | The graphic of the decimal logarithm of the released amount of drug versus time is linear. | |